Skip to main content
main-content

Expert interviews

medwireNews@ECTRIMS 2018

13-10-2018 | Multiple sclerosis | Video

ECTRIMS 2018: Novel 3-in-1 MS-SMART trial fails on efficacy end-points but paves the way for multi-arm strategies

Jeremy Chataway reports on the latest findings from the MS-SMART trial that evaluated the efficacy of amiloride, fluoxetine and riluzole versus placebo in reducing disability in progressive multiple sclerosis as a way of speeding up phase II trial activity (2:57).

12-10-2018 | Multiple sclerosis | Video

ECTRIMS 2018: : ORATORIO extension-phase trial findings show sustained reduction in MS disability progression with ocrelizumab

Jerry Wolinksy summarises his findings from the open-label extension period of the phase III ORATORIO trial looking at sustained disability progression with ocrelizumab in patients with primary progressive multiple sclerosis (8:20).

12-10-2018 | Multiple sclerosis | Video

ECTRIMS 2018: Sensitivity for predicting a second MS episode increased with McDonald 2017 criteria

Roos M van der Vuurst de Vries discusses her McDonald 2017 criteria findings, which provide further support of improved sensitivity for diagnosing clinically definite multiple sclerosis in patients with clinically isolated syndrome (5:05).

12-10-2018 | Multiple sclerosis | Video

ECTRIMS 2018: McDonald 2017 criteria allows for earlier MS diagnosis than McDonald 2010 in patients with clinically isolated syndrome

Wallace Brownlee presents his study showing that the revised McDonald 2017 criteria are more sensitive than the McDonald 2010 criteria, albeit with a modest reduction in specificity, for diagnosing multiple sclerosis in patients with typical clinically isolated syndrome characteristics (3:49).

12-10-2018 | Multiple sclerosis | Video

ECTRIMS 2018: Real-world data support early treatment initiation in relapsing-remitting MS patients

Pietro Iaffaldano shares his real-world findings from the Big Multiple Sclerosis Data Network showing an optimal time to treatment initiation of 6 months in patients with relapsing-remitting multiple sclerosis (1:51).

12-10-2018 | Multiple sclerosis | Video

ECTRIMS 2018: Focal inflammatory brain disease associated with increased risk for cognitive disability in relapse-onset MS

Wallace Brownlee talks about his group’s findings that conventional MRI measures of inflammatory disease could help identify patients with early multiple sclerosis who are at high risk of developing cognitive disability (3:05).

11-10-2018 | Multiple sclerosis | Video

ECTRIMS 2018: Focal cortical damage identifies MS patients at increased risk of frequent early relapses

Antonio Scalfari gives an overview of findings showing that early focal cortical lesions at multiple sclerosis onset is associated with earlier relapse and an increased risk of converting to secondary progressive multiple sclerosis (4:14).  

11-10-2018 | Multiple sclerosis | Video

ECTRIMS 2018: Better outcomes in relapsing MS patients switching to natalizumb versus fingolimod after first-line treatment

Tim Spelman discusses his team’s findings of a significant reduction in relapse rates and greater disability improvement in multiple sclerosis patients who relapse on first-line treatment and switch to natalizumab versus fingolimod (2:55).

10-10-2018 | Multiple sclerosis | Video

ECTRIMS 2018: Ongoing relapse activity is a suitable treatment target in secondary-progressive multiple sclerosis

Nathaniel Lizak presents study findings showing that ongoing relapse in patients with multiple sclerosis is not a contraindication to disease-modifying treatment (2:19).

Image Credits